Towards stem cell replacement therapies for Parkinson's disease

Biochemical and Biophysical Research Communications

Volumn 396, Issue 1, 2010, Pages 152-156

  Arenas, Ernest ^a  

^a Exp Dermatology Research Group   (Sweden)

Author keywords

Clinical trials; Differentiation; Embryonic stem cells; iPS; Nuclear receptors; Wnt

Indexed keywords

ASCORBIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FIBROBLAST GROWTH FACTOR 8; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA3;

ARTICLE; BRAIN DEPTH STIMULATION; CELL CULTURE; CELL LOSS; CELL REGENERATION; CELL TYPE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DYSKINESIA; EMBRYONIC STEM CELL; HUMAN; LEWY BODY; MEDICAL RESEARCH; MESENCEPHALON; NERVE CELL DIFFERENTIATION; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TISSUE GRAFT; TREATMENT OUTCOME;

CELL CULTURE TECHNIQUES; DOPAMINE; EMBRYONIC STEM CELLS; FETUS; HUMANS; MESENCEPHALON; NERVE REGENERATION; NEUROGENESIS; NEURONS; PARKINSON DISEASE;

IPS;

EID: 77952295552     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.04.037     Document Type: Article

References (39)

1. Hawkes C.H., Del Tredici K., and Braak H. Parkinson's disease: the dual hit theory revisited. Ann. NY Acad. Sci. 1170 (2009) 615-622
2. Lesage S., and Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18 (2009) R48-R59
3. Piccini P., Brooks D.J., Björklund A., et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 2 (1999) 1137-1140
4. Freed C.R., Greene P.E., Breeze R.E., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (2001) 710-719
5. Olanow C.W., Goetz C.G., Kordower J.H., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54 (2003) 403-414
6. Hagell P., and Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J. Neuropathol. Exp. Neurol. 60 (2001) 741-752
7. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150 (2007) 963-976
8. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119 (2009) 182-192
9. Hagell P., Piccini P., Björklund A., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 5 (2002) 627-628
10. Carlsson T., Carta M., Muñoz A., et al. Impact of grafted serotonin and dopamine neurons on development of l-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 132 (2009) 319-335
11. Thompson L., Barraud P., Andersson E., et al. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J. Neurosci. 25 (2005) 6467-6477
12. Kordower J.H., Chu Y., Hauser R.A., et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14 (2008) 504-506
13. Li J.Y., Englund E., Holton J.L., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14 (2008) 501-503
14. Mendez I., Viñuela A., Astradsson A., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14 (2008) 507-509
15. Kriks S., and Studer L. Protocols for generating ES cell-derived dopamine neurons. Adv. Exp. Med. Biol. 651 (2009) 101-111
16. Lindvall O., and Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol. Sci. 30 (2009) 260-267
17. Kiskinis E., and Eggan K. Progress toward the clinical application of patient-specific pluripotent stem cells. J. Clin. Invest. 120 (2010) 51-59
18. Perrier A.L., Tabar V., Barberi T., et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 101 (2004) 12543-12548
19. Kawasaki H., Mizuseki K., Nishikawa S., et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28 (2000) 31-40
20. Roy N.S., Cleren C., Singh S.K., et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12 (2006) 1259-1268
21. Wagner J., Akerud P., Castro D.S., et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat. Biotechnol. 17 (1999) 653-659
22. Andersson E., Tryggvason U., Deng Q., et al. Identification of intrinsic determinants of midbrain dopamine neurons. Cell 124 (2006) 393-405
23. Friling S., Andersson E., Thompson L.H., et al. Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc. Natl. Acad. Sci. USA 106 (2009) 7613-7618
24. Schwartz C.M., Spivak C.E., Baker S.C., et al. NTera2: a model system to study dopaminergic differentiation of human embryonic stem cells. Stem Cells Dev. 14 (2005) 517-534
25. Castelo-Branco G., Sousa K.M., Bryja V., et al. Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. Mol. Cell. Neurosci. 31 (2006) 251-262
26. Vazin T., Chen J., Lee C.T., et al. Assessment of stromal-derived inducing activity in the generation of dopaminergic neurons from human embryonic stem cells. Stem Cells 26 (2008) 1517-1525
27. Sacchetti P., Sousa K.M., Hall A.C., et al. Liver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells. Cell Stem Cell 5 (2009) 409-419
28. Castelo-Branco G., Wagner J., Rodriguez F.J., et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl. Acad. Sci. USA 100 (2003) 12747-12752
29. Andersson E.R., Prakash N., Cajanek L., et al. Wnt5a regulates ventral midbrain morphogenesis and the development of A9-A10 dopaminergic cells in vivo. PLoS One 3 (2008) e3517
30. Parish C.L., Castelo-Branco G., Rawal N., et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J. Clin. Invest. 118 (2008) 149-160
31. Koch P., Opitz T., Steinbeck J.A., et al. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc. Natl. Acad. Sci. USA 106 (2009) 3225-3230
32. Cho M.S., Lee Y.E., Kim J.Y., et al. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 105 (2008) 3392-3397
33. Chambers S.M., Fasano C.A., Papapetrou E.P., et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27 (2009) 275-280
34. Park I.H., Arora N., Huo H., et al. Disease-specific induced pluripotent stem cells. Cell 134 (2008) 877-886
35. Soldner F., Hockemeyer D., Beard C., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136 (2009) 964-977
36. Wernig M., Zhao J.P., Pruszak J., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc. Natl. Acad. Sci. USA 105 (2008) 5856-5861
37. Li W., and Ding S. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol. Sci. 31 (2010) 36-45
38. Krizhanovsky V., and Lowe S.W. Stem cells: the promises and perils of p53. Nature 460 (2009) 1085-1086
39. Vierbuchen T., Ostermeier A., Pang Z.P., et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463 (2010) 1035-1041